These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
708 related articles for article (PubMed ID: 29305295)
1. The Hippo pathway in normal development and cancer. Maugeri-Saccà M; De Maria R Pharmacol Ther; 2018 Jun; 186():60-72. PubMed ID: 29305295 [TBL] [Abstract][Full Text] [Related]
2. YAP/TAZ for cancer therapy: opportunities and challenges (review). Guo L; Teng L Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178 [TBL] [Abstract][Full Text] [Related]
3. Arhgef7 promotes activation of the Hippo pathway core kinase Lats. Heidary Arash E; Song KM; Song S; Shiban A; Attisano L EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573 [TBL] [Abstract][Full Text] [Related]
4. [Research advances in the role of the Hippo-YAP/TAZ signaling pathway in primary liver cancer]. Guo LW; Shao GL Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):878-880. PubMed ID: 29325286 [TBL] [Abstract][Full Text] [Related]
5. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway. Jang JW; Kim MK; Bae SC Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552 [TBL] [Abstract][Full Text] [Related]
6. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy. Zhu J; Wu T; Lin Q Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351 [TBL] [Abstract][Full Text] [Related]
7. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471 [TBL] [Abstract][Full Text] [Related]
8. YAP/TAZ at the Roots of Cancer. Zanconato F; Cordenonsi M; Piccolo S Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434 [TBL] [Abstract][Full Text] [Related]
9. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201 [TBL] [Abstract][Full Text] [Related]
10. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review. Crawford JJ; Bronner SM; Zbieg JR Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112 [No Abstract] [Full Text] [Related]
11. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma. Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849 [TBL] [Abstract][Full Text] [Related]
12. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539 [TBL] [Abstract][Full Text] [Related]
13. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade. Budel SJ; Penning MM; Penning LC Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400 [TBL] [Abstract][Full Text] [Related]
14. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. Kim M; Kim T; Johnson RL; Lim DS Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714 [TBL] [Abstract][Full Text] [Related]
15. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Kim MH; Kim J Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640 [TBL] [Abstract][Full Text] [Related]
16. The Hippo Pathway in Prostate Cancer. Salem O; Hansen CG Cells; 2019 Apr; 8(4):. PubMed ID: 31018586 [TBL] [Abstract][Full Text] [Related]
17. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634 [TBL] [Abstract][Full Text] [Related]
18. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Chen M; Wang M; Xu S; Guo X; Jiang J Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204 [TBL] [Abstract][Full Text] [Related]
19. Metabolic control of YAP and TAZ by the mevalonate pathway. Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687 [TBL] [Abstract][Full Text] [Related]
20. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]